ARQT
Price
$23.89
Change
+$0.51 (+2.18%)
Updated
Sep 11 closing price
Capitalization
3B
47 days until earnings call
Intraday BUY SELL Signals
NUVB
Price
$6.07
Change
-$0.21 (-3.34%)
Updated
Sep 11 closing price
Capitalization
2.13B
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARQT vs NUVB

ARQT vs NUVB Comparison Chart in %
View a ticker or compare two or three
VS
ARQT vs. NUVB commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a Hold and NUVB is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARQT($3B) has a higher market cap than NUVB($2.13B). ARQT YTD gains are higher at: -17.751 vs. NUVB (-32.254). ARQT has higher annual earnings (EBITDA): 45.4M vs. NUVB (-121.01M). NUVB has more cash in the bank: 661M vs. ARQT (239M). ARQT has less debt than NUVB: ARQT (114M) vs NUVB (252M). ARQT has higher revenues than NUVB: ARQT (464M) vs NUVB (170M).
ARQTNUVBARQT / NUVB
Capitalization3B2.13B141%
EBITDA45.4M-121.01M-38%
Gain YTD-17.751-32.25455%
P/E Ratio108.59N/A-
Revenue464M170M273%
Total Cash239M661M36%
Total Debt114M252M45%
FUNDAMENTALS RATINGS
ARQT vs NUVB: Fundamental Ratings
ARQT
NUVB
OUTLOOK RATING
1..100
6882
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
47
Fair valued
PROFIT vs RISK RATING
1..100
89100
SMR RATING
1..100
5498
PRICE GROWTH RATING
1..100
5638
P/E GROWTH RATING
1..100
52100
SEASONALITY SCORE
1..100
n/a3

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NUVB's Valuation (47) in the null industry is somewhat better than the same rating for ARQT (92). This means that NUVB’s stock grew somewhat faster than ARQT’s over the last 12 months.

ARQT's Profit vs Risk Rating (89) in the null industry is in the same range as NUVB (100). This means that ARQT’s stock grew similarly to NUVB’s over the last 12 months.

ARQT's SMR Rating (54) in the null industry is somewhat better than the same rating for NUVB (98). This means that ARQT’s stock grew somewhat faster than NUVB’s over the last 12 months.

NUVB's Price Growth Rating (38) in the null industry is in the same range as ARQT (56). This means that NUVB’s stock grew similarly to ARQT’s over the last 12 months.

ARQT's P/E Growth Rating (52) in the null industry is somewhat better than the same rating for NUVB (100). This means that ARQT’s stock grew somewhat faster than NUVB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARQTNUVB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 26 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (ARQT: $23.89 vs. NUVB: $6.07)
Brand notoriety: ARQT and NUVB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 123% vs. NUVB: 76%
Market capitalization -- ARQT: $3B vs. NUVB: $2.13B
ARQT [@Biotechnology] is valued at $3B. NUVB’s [@Biotechnology] market capitalization is $2.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 0 FA rating(s) are green while NUVB’s FA Score has 0 green FA rating(s).

  • ARQT’s FA Score: 0 green, 5 red.
  • NUVB’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVB is a better buy in the long-term than ARQT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 3 TA indicator(s) are bullish while NUVB’s TA Score has 5 bullish TA indicator(s).

  • ARQT’s TA Score: 3 bullish, 5 bearish.
  • NUVB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NUVB is a better buy in the short-term than ARQT.

Price Growth

ARQT (@Biotechnology) experienced а -0.06% price change this week, while NUVB (@Biotechnology) price change was -10.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

ARQT is expected to report earnings on Oct 29, 2026.

NUVB is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARQT
Daily Signal:
Gain/Loss:
NUVB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IHD7.670.09
+1.19%
VOYA EMERGING MARKETS HIGH Income DIVIDEND EQUITY FUND
CALI50.160.06
+0.12%
iShares Short-Term CA Muni Act ETF
IBDR24.19N/A
N/A
iShares iBonds Dec 2026 Term Corp ETF
BESF41.60N/A
N/A
Bastion Energy ETF
BFXU23.42N/A
N/A
FT Vest Laddered U.S. Eq Unc Acc ETF